Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T10464 |
Atuveciclib
BAY-1143572 |
CDK | Cell Cycle/Checkpoint |
Atuveciclib (BAY-1143572) 是一种有效且高度选择性的口服 PTEFb/CDK9抑制剂。Atuveciclib (BAY-1143572) 抑制 CDK9/CycT1,IC50为 13 nM。 | |||
T10464L |
Atuveciclib Racemate
BAY-1143572 Racemate,阿维西利 |
CDK | Cell Cycle/Checkpoint |
Atuveciclib Racemate (BAY-1143572 Racemate) 是 Atuveciclib 的外消旋混合物。 Atuveciclib 是口服有效的 P-TEFb/CDK9高选择性抑制剂,CDK9/CycT1的 IC50为13 nM。 | |||
T10465 |
Atuveciclib S-Enantiomer
BAY-1143572 S-Enantiomer |
CDK | Cell Cycle/Checkpoint |
Atuveciclib S-Enantiomer (BAY-1143572 S-Enantiomer) 是 BAY-1143572的 S-对映异构体 ,是一种有效的选择性 CDK9抑制剂,抑制 CDK9/CycT1,IC50为 16 nM。 | |||
T70897 | Zotiraciclib HCl | ||
Zotiraciclib, also known as TG02 and SB1317, is a novel small molecule potent CDK/JAK2/FLT3 inhibitor. Zotiraciclib may be useful for the treatment of cancer that crosses the blood brain barrier and acts by depleting Myc through the inhibition of cyclin-dependent kinase 9 (CDK9). It is one of a number of CDK inhibitors under investigation; others targeting CDK9 for the treatment of acute myeloid leukemia include alvocidib and atuveciclib. Myc overexpression is a known factor in many cancers, w... |